| Literature DB >> 27441746 |
Everett J Moding1, Yvonne M Mowery, David G Kirsch.
Abstract
Stereotactic body radiation therapy (SBRT) utilizing a small number of high-dose radiation therapy fractions continues to expand in clinical application. Although many approaches have been proposed to radiosensitize tumors with conventional fractionation, how these radiosensitizers will translate to SBRT remains largely unknown. Here, we review our current understanding of how SBRT eradicates tumors, including the potential contributions of endothelial cell death and immune system activation. In addition, we identify several new opportunities for radiosensitization generated by the move toward high dose per fraction radiation therapy.Entities:
Mesh:
Year: 2016 PMID: 27441746 PMCID: PMC4957656 DOI: 10.1097/PPO.0000000000000203
Source DB: PubMed Journal: Cancer J ISSN: 1528-9117 Impact factor: 3.360